2025 Tutorial on Neoplastic Hematopathology (Slides only)

Hematopathology • Hematologic Malignancies • Lymphoma • Leukemia • Myeloid Neoplasms • Molecular Pathology

Build a comprehensive diagnostic framework for hematologic malignancies with 2025 Tutorial on Neoplastic Hematopathology (Slides only), based on the long-running Tutorial on Neoplastic Hematopathology: Focus on New Classifications.

Continuing a tradition of more than four decades of hematopathology education, the 2025 course was held January 20–24, 2025, at the Renaissance Phoenix Downtown Hotel in Phoenix, Arizona, under the direction of Daniel A. Arber, MD. The program was designed to update physicians on contemporary diagnostic problems, classification systems, immunophenotypic findings, molecular genetics, and clinically relevant developments across neoplastic hematopathology.

The curriculum spans lymphoid neoplasms, leukemias, plasma cell disorders, myeloid neoplasms, histiocytic disease, mastocytosis, immunodeficiency-associated lymphoproliferative disorders, pediatric and germline predisposition syndromes, and molecularly defined hematologic malignancies.

Course Details

• Course: 2025 Tutorial on Neoplastic Hematopathology
• Official Subtitle: Focus on New Classifications
• Year: 2025
• Dates: January 20–24, 2025
• Venue: Renaissance Phoenix Downtown Hotel
• Location: Phoenix, Arizona, USA
• Original Provider: University of Chicago
• Department: Department of Pathology
• CME Provider: University of Chicago Pritzker School of Medicine
• Course Director: Daniel A. Arber, MD
• Associate Course Director: Attilio Orazi, MD
• Specialty: Hematopathology
• Primary Focus: Neoplastic Hematopathology / Hematologic Malignancies
• MedicalAmboss Format: Slides only
• Original Live Activity: Up to 33.75 AMA PRA Category 1 Credits™
• ABPath Lifelong Learning: Up to 33.75 Credits
• Language: English

The official course ran from January 20 through January 24, 2025, with the live meeting held in Phoenix.

Course Overview

Modern hematopathology requires integration of several complementary forms of diagnostic information.

A hematologic malignancy may require assessment of:

Morphology → Immunophenotype → Molecular Genetics → Cytogenetics → Clinical Findings → Classification → Prognostic & Therapeutic Significance

The 2025 Tutorial on Neoplastic Hematopathology focuses on applying this integrated approach across lymphoid and myeloid malignancies.

The program includes both foundational and advanced subjects, beginning with normal and reactive lymph-node pathology before progressing into increasingly complex neoplastic entities.

Major areas include:

• Reactive lymphoid pathology
• Lymphoma classification
• B-cell leukemias
• T/NK-cell leukemias
• Follicular lymphoma
• Mantle cell lymphoma
• Marginal zone lymphoma
• Aggressive B-cell lymphoma
• T-cell lymphoma
• Hodgkin lymphoma
• Acute lymphoblastic leukemia
• Acute myeloid leukemia
• Myeloproliferative neoplasms
• Myelodysplastic syndromes
• Plasma cell neoplasms
• Histiocytic disorders
• Mastocytosis
• Germline predisposition syndromes
• Molecular and immunologic diagnostics

Learning Objectives

At the conclusion of this activity, participants will be able to:

• Identify how to evaluate and respond to diagnostic problems that arise in neoplastic hematopathology;
• State how to utilize recent advances in the classification of hematopoietic tumors;
• Discuss how to interpret and apply immunologic and molecular genetic findings in the diagnosis of neoplastic hematologic disease;
• Describe how to implement the most recent classification of hematologic neoplasms;
• Recall new discoveries that might impact future classifications of hematologic neoplasms;
• Understand the prognostic and therapeutic significance of new molecular genetic markers of these tumors.

These objectives are listed by the University of Chicago for the official activity.

ACGME / ABMS Core Competencies

The activity identifies the following core competencies:

• Medical Knowledge
• Practice-based Learning and Improvement

Neoplastic Hematopathology

Hematopathology increasingly relies on a multidisciplinary diagnostic model.

Accurate classification may require integration of:

• Histologic morphology
• Bone marrow findings
• Peripheral blood findings
• Flow cytometry
• Immunohistochemistry
• Cytogenetics
• Fluorescence in situ hybridization
• Molecular genetic testing
• Clinical presentation

The course emphasizes how these findings interact rather than treating each diagnostic modality in isolation.

Current Classification of Hematologic Neoplasms

A central theme of the 2025 tutorial is the application of contemporary classification systems for hematopoietic tumors.

Classification is important because the diagnostic label can influence:

• Prognosis
• Molecular testing
• Treatment selection
• Eligibility for targeted therapies
• Clinical-trial classification
• Patient counseling

The course reviews both lymphoid and myeloid classification across the five-day program.

Day 1 – Lymphoid Pathology & B-Cell Neoplasms

Normal Lymph Nodes and Reactive Hyperplasias

Rebecca King, MD

Understanding normal lymph-node architecture and reactive patterns is essential before diagnosing lymphoma.

The session provides a foundation for distinguishing:

Reactive Process → Atypical Proliferation → Neoplastic Lymphoid Disease

Introduction to the Classification of Lymphoma

James Cook, MD

This session introduces the framework used to classify lymphoid malignancies.

Classification integrates:

• Morphology
• Cell lineage
• Immunophenotype
• Genetics
• Clinical presentation
• Disease distribution

The goal is to assign lymphoid neoplasms to biologically and clinically meaningful entities.

Monoclonal B Lymphocytosis, CLL & Related B-Cell Leukemias

Kathy Foucar, MD

This session reviews:

• Monoclonal B lymphocytosis
• Chronic lymphocytic leukemia
• Related mature B-cell leukemias
• Diagnostic distinctions
• Classification
• Immunophenotypic features

A practical distinction between precursor or limited clonal populations and established leukemia can carry important clinical implications.

Chronic T/NK Cell Leukemias

Kathy Foucar, MD

The curriculum extends into chronic neoplasms derived from:

• T lymphocytes
• Natural killer cells

The session emphasizes diagnostic recognition and classification of these less common hematologic malignancies.

Lymphoplasmacytic & Marginal Zone Lymphomas

James Cook, MD, PhD

The program covers:

• Lymphoplasmacytic lymphoma
• Nodal marginal zone lymphoma
• Extranodal marginal zone lymphoma

These entities can demonstrate overlapping morphology, making integration of clinical and ancillary information particularly important.

Mantle Cell Lymphoma, Follicular Lymphoma & Variants

Rebecca King, MD

The course reviews two important mature B-cell lymphoma groups:

• Mantle cell lymphoma
• Follicular lymphoma

with attention to recognized variants and diagnostic problems.

Day 2 – T-Cell, Acute Lymphoid & Aggressive B-Cell Neoplasms

Peripheral T-Cell Lymphoma & Anaplastic Large Cell Lymphoma

Elaine Jaffe, MD

T-cell lymphomas represent some of the more challenging areas of hematopathology.

The session includes:

• Peripheral T-cell lymphoma
• Anaplastic large cell lymphoma
• Morphologic assessment
• Immunophenotypic evaluation
• Classification

Acute Lymphoblastic Leukemia / Lymphoma

Michael Borowitz, MD

The course reviews:

• Acute lymphoblastic leukemia
• Lymphoblastic lymphoma
• Acute leukemias of ambiguous lineage

Classification requires careful determination of lineage and incorporation of modern immunophenotypic and molecular findings.

Acute Leukemias of Ambiguous Lineage

Some acute leukemias show overlapping or indeterminate lineage features.

Diagnostic evaluation may involve:

Morphology → Flow Cytometry → Immunophenotyping → Genetics → Integrated Classification

Correct lineage assignment has direct implications for therapy.

Diffuse, Aggressive B-Cell Lymphomas

Rebecca King, MD

Aggressive B-cell neoplasms can represent a diagnostically complex group.

Important considerations include:

• Morphology
• Clinical behavior
• Immunophenotype
• Molecular findings
• High-grade features
• Differential diagnosis

Lymphoma Diagnosis: A Clinician’s Perspective

Javier Munoz, MD, MBA

The program also presents lymphoma diagnosis from the treating clinician’s perspective.

This helps connect:

Pathologic Diagnosis → Clinical Staging → Prognostic Assessment → Treatment Selection

Day 3 – Splenic, Hodgkin, Histiocytic & Cutaneous Disorders

Splenic Tumors

Daniel Arber, MD

Splenic hematologic lesions may present unique diagnostic challenges because several lymphoid and other hematopoietic disorders can involve the spleen.

The session addresses the diagnostic approach to splenic tumors within current classification systems.

Hodgkin Lymphoma

Amy Chadburn, MD

The course reviews Hodgkin lymphoma, including its pathologic classification and diagnostic differentiation from morphologic mimics.

Diagnostic workup may incorporate:

• Architecture
• Cytology
• Immunophenotype
• Clinical setting

Immunodeficiency- and Viral-Associated Lymphoproliferations

Jonathan Said, MD

Immune dysfunction and viral infection can lead to a spectrum of lymphoid proliferations.

The session reviews these disorders within their clinical and pathological context.

Histiocytic Disorders

Amy Chadburn, MD

Histiocytic disorders include uncommon but diagnostically important entities that may require specialized immunophenotypic and molecular evaluation.

Cutaneous Lymphomas

Jonathan Said, MD

Cutaneous lymphomas require integration of:

Skin Histology + Immunophenotype + Clinical Distribution + Systemic Evaluation

The course reviews neoplastic lymphoid processes presenting primarily in the skin.

Day 4 – Myeloid Neoplasms & Plasma Cell Disease

Introduction to the Classification of Myeloid Neoplasms and Acute Leukemia

Daniel Arber, MD

The myeloid component begins with an overview of contemporary classification.

Modern myeloid diagnosis increasingly depends on:

• Morphology
• Blast percentage
• Cytogenetic abnormalities
• Molecular findings
• Disease-defining genetic lesions
• Clinical history

Chronic Myeloid Leukemia

Adam Bagg, MD

The curriculum includes a focused review of chronic myeloid leukemia (CML) and its place within modern myeloid-neoplasm classification.

BCR::ABL1-Negative Myeloproliferative Neoplasms

Attilio Orazi, MD

This session reviews myeloproliferative neoplasms not defined by BCR::ABL1.

Evaluation commonly integrates:

Blood Counts + Bone Marrow Morphology + Molecular Markers + Clinical Findings

Eosinophilic Disorders

Adam Bagg, MD

Eosinophilia can result from both reactive processes and clonal hematologic disease.

The session addresses diagnostic assessment of eosinophilic disorders in hematopathology.

Clonal Cytopenias & Myelodysplastic Syndrome

Robert Hasserjian, MD

The program covers:

• Clonal cytopenias
• Myelodysplastic syndrome
• Morphologic evaluation
• Molecular findings
• Current classification

Distinguishing early clonal disease from established myeloid neoplasia is an increasingly important diagnostic challenge.

Pediatric & Germline Predisposition Syndromes

Robert Lorsbach, MD

Inherited susceptibility to hematologic malignancy has become increasingly important as molecular testing identifies germline predisposition syndromes.

Recognition can influence:

• Diagnosis
• Family counseling
• Donor selection
• Surveillance
• Clinical management

Plasma Cell Neoplasms

Robert Lorsbach, MD, PhD

The curriculum includes plasma cell neoplasms and their diagnostic classification.

Assessment can involve:

• Bone marrow morphology
• Plasma cell burden
• Immunophenotype
• Serum and urine findings
• Molecular / cytogenetic studies
• Clinical features

Day 5 – Advanced Myeloid Neoplasia

Myelodysplastic / Myeloproliferative Neoplasms

Attilio Orazi, MD

MDS/MPN disorders contain overlapping dysplastic and proliferative features.

Their diagnosis requires integration of:

Peripheral Blood + Bone Marrow Morphology + Molecular Findings + Exclusion Criteria

Acute Myeloid Leukemias

Daniel Arber, MD

AML classification has become increasingly genetics-driven.

The session addresses contemporary approaches to acute myeloid leukemia, where diagnosis may incorporate:

• Morphology
• Cytogenetics
• Molecular abnormalities
• Prior disease history
• Therapy-related context

The increasing importance of genetic information reflects one of the central learning objectives of the course.

Mastocytosis

Attilio Orazi, MD

The final disease-focused session reviews mastocytosis, including pathologic recognition and classification.

The course concludes with case presentations and discussion led by Daniel Arber and Attilio Orazi.

Molecular Genetics in Hematopathology

Molecular genetic testing is now central to many hematologic diagnoses.

Genetic findings may help:

• Establish a diagnosis
• Define a disease entity
• Refine classification
• Determine prognosis
• Identify therapeutic targets
• Monitor disease
• Distinguish clonal from reactive processes

One of the official learning objectives specifically focuses on understanding the prognostic and therapeutic significance of new molecular genetic markers.

Immunophenotyping

Immunologic findings remain essential in hematopathology.

Common diagnostic tools include:

• Flow cytometry
• Immunohistochemistry
• Lineage markers
• Maturation markers
• Aberrant antigen-expression patterns

The course emphasizes applying immunologic information together with morphology and genetics rather than interpreting results independently.

Integrated Hematopathology Diagnosis

The broad diagnostic approach reinforced throughout the tutorial can be summarized as:

Clinical Information → Morphology → Flow Cytometry / IHC → Cytogenetics → Molecular Genetics → Classification → Clinical Interpretation

This integrated approach is particularly important because many modern hematologic entities are defined not by morphology alone but by combinations of pathologic and molecular findings.

Case-Based Learning

The official five-day program includes multiple case presentation sessions.

Cases follow major teaching blocks involving:

• B-cell neoplasms
• T-cell and acute lymphoid neoplasms
• Hodgkin and related disorders
• Myeloid and plasma cell disorders
• Acute leukemia and mastocytosis

Case-based education helps translate classification criteria and ancillary testing into practical diagnostic decision-making.

Course Leadership

Daniel A. Arber, MD — Course Director

• Donald West and Mary Elizabeth King Professor
• Chair, Department of Pathology
• University of Chicago

Attilio Orazi, MD — Associate Course Director

• Professor and Chair, Department of Pathology
• Texas Tech University

These roles are listed by the University of Chicago CME program for the 2025 tutorial.

Target Audience

This activity is designed for:

• Pathologists
• Hematopathologists
• Surgical Pathologists
• Pathologists-in-Training
• Pathology Residents
• Hematopathology Fellows
• Medical Oncologists
• Hematologists
• Other healthcare professionals dedicated to the diagnosis of hematological malignancies

The University of Chicago specifically identifies the activity for pathologists and healthcare professionals dedicated to diagnosing hematological malignancies, while the course overview highlights pathologists-in-training and medical oncologists/hematologists.

Who Should Take This Course?

2025 Tutorial on Neoplastic Hematopathology (Slides only) is particularly relevant for professionals seeking advanced updates in:

• Hematopathology
• Hematologic malignancies
• Lymphoma
• Leukemia
• Myeloid neoplasms
• Plasma cell neoplasms
• Molecular pathology
• Flow cytometry
• Immunohistochemistry
• Molecular genetics
• WHO / contemporary hematologic classification
• Bone marrow pathology
• Diagnostic hematology

Why This Course Is Useful

The strength of the 2025 Tutorial on Neoplastic Hematopathology is its broad, systematic coverage of hematologic malignancies under contemporary classification frameworks.

The educational progression can be summarized as:

Reactive Lymphoid Pathology → B-Cell Neoplasms → T/NK Neoplasms → Hodgkin & Cutaneous Lymphomas → Acute Lymphoid Disease → Myeloid Neoplasms → Plasma Cell Disease → Acute Myeloid Leukemia

The course also emphasizes the increasing role of:

Immunophenotyping + Cytogenetics + Molecular Genetics

in defining and managing hematologic neoplasms.

Original Conference Accreditation

The University of Chicago Pritzker School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

For the original live 2025 conference:

• Up to 33.75 AMA PRA Category 1 Credits™
• Up to 33.75 ABPath Lifelong Learning CME Credits
• 33.75 Participation Credits

The official activity ran from January 20–24, 2025.

Important CME / Certificate Notice

The MedicalAmboss product is identified as Slides only.

Therefore, if this product consists only of independently delivered slide files, do not advertise:

• 33.75 CME Credits Included
• 33.75 ABPath Credits Included
• Official University of Chicago Certificate Included
• Official Conference Registration Included
• CME Claiming Access Included

unless official University of Chicago participation and credit-claiming access are actually part of the product.

The safer wording is:

Original University of Chicago Live Activity: Up to 33.75 AMA PRA Category 1 Credits™

Short Description

2025 Tutorial on Neoplastic Hematopathology (Slides only) provides an in-depth review of contemporary diagnosis and classification of hematologic malignancies.

Directed by Daniel A. Arber, MD, the original University of Chicago course was held January 20–24, 2025, at the Renaissance Phoenix Downtown Hotel in Phoenix, Arizona.

The curriculum covers lymphoma classification, CLL and B-cell leukemias, T/NK-cell neoplasms, follicular and mantle cell lymphoma, peripheral T-cell lymphoma, acute lymphoblastic leukemia, aggressive B-cell lymphoma, Hodgkin lymphoma, immunodeficiency-associated lymphoproliferations, histiocytic disorders, cutaneous lymphoma, chronic myeloid leukemia, myeloproliferative neoplasms, eosinophilic disorders, myelodysplastic syndromes, germline predisposition syndromes, plasma cell neoplasms, AML, MDS/MPN and mastocytosis.

Provider: University of Chicago
Course Director: Daniel A. Arber, MD
Associate Course Director: Attilio Orazi, MD
Dates: January 20–24, 2025
Location: Phoenix, Arizona
Format: Slides only
Specialty: Hematopathology
Original Live Activity: Up to 33.75 AMA PRA Category 1 Credits™

Topics

January 20, 2025

• Normal Lymph Nodes and Reactive Hyperplasias — Rebecca King, MD
• Introduction to the Classification of Lymphoma — James Cook, MD
• Monoclonal B Lymphocytosis, Chronic Lymphocytic Leukemia and Related B-Cell Leukemias — Kathy Foucar, MD
• Chronic T/NK Cell Leukemias — Kathy Foucar, MD
• Lymphoplasmacytic Lymphoma and Nodal and Extranodal Marginal Zone Lymphoma — James Cook, MD, PhD
• Mantle Cell Lymphoma, Follicular Lymphoma and Variants — Rebecca King, MD
• Case Presentations — Rebecca King, MD; James Cook, MD, PhD; Kathy Foucar, MD

January 21, 2025

• Peripheral T Cell Lymphoma and Anaplastic Large Cell Lymphoma — Elaine Jaffe, MD
• Acute Lymphoblastic Leukemia/Lymphoma and Acute Leukemias of Ambiguous Lineage — Michael Borowitz, MD
• Case Presentations — Michael Borowitz, MD; Elaine Jaffe, MD
• Diffuse, Aggressive B Cell Lymphomas — Rebecca King, MD
• Lymphoma Diagnosis: A Clinician’s Perspective — Javier Munoz, MD, MBA
• Case Presentations — Rebecca King, MD

January 22, 2025

• Splenic Tumors — Daniel Arber, MD
• Hodgkin Lymphoma — Amy Chadburn, MD
• Immunodeficiency- and Viral-Associated Lymphoproliferations — Jonathan Said, MD
• Histiocytic Disorders — Amy Chadburn, MD
• Cutaneous Lymphomas — Jonathan Said, MD
• Case Presentations — Daniel Arber, MD; Jonathan Said, MD; Amy Chadburn, MD

January 23, 2025

• Introduction to the Classification of Myeloid Neoplasms and Acute Leukemia — Daniel Arber, MD
• Chronic Myeloid Leukemia — Adam Bagg, MD
• BCR::ABL1-Negative Myeloproliferative Neoplasms — Attilio Orazi, MD
• Eosinophilic Disorders — Adam Bagg, MD
• Clonal Cytopenias and Myelodysplastic Syndrome — Robert Hasserjian, MD
• Pediatric and Germline Predisposition Syndromes — Robert Lorsbach, MD
• Plasma Cell Neoplasms — Robert Lorsbach, MD, PhD
• Case Presentations — Robert Hasserjian, MD; Robert Lorsbach, MD, PhD

January 24, 2025

• Myelodysplastic/Myeloproliferative Neoplasms — Attilio Orazi, MD
• Acute Myeloid Leukemias — Daniel Arber, MD
• Mastocytosis — Attilio Orazi, MD
• Case Presentations — Daniel Arber, MD; Attilio Orazi, MD

The lecture titles, faculty, and schedule above follow the official University of Chicago 2025 program.